A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed Study LP352-301 or LP352-302. The study consists of 3 main phases: Screening, Titration period and Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 14 months.

NCT Number	NCT06908226
Lead Sponsor	Longboard Pharmaceuticals
Conditions	Developmental and Epileptic Encephalopathy
Enrollment	324 participants
Start Date	2025-02-12
Primary Completion	2027-11-11 (estimated)
Study Completion	2027-12-17 (estimated)
Updated on ClinicalTrials.gov	2026-08-12